>

Harish Manwani - Gilead Sciences Director

<div class='circular--portrait' style='background:#FCD202;color: white;font-size:3em;padding-top: 40px;;'>GIL</div>
  Director
Mr. Harish M. Manwani serves as Independent Director of the Company. Mr. Manwani is a Senior Operating Partner at The Blackstone Group L.P., a leading global alternative asset manager, which he joined in 2015. He previously was Chief Operating Officer of the Unilever Group from 2011 until his retirement in 2014. Mr. Manwani joined Unilever in 1976 as a management trainee in India and held senior management roles around the world, including North America, Latin America and Asia. He is also the Chairman of Board of the Indian School of Business. Mr. Manwani is an honors graduate from Mumbai University. He holds a masters degree in Management Studies, and he attended the Advanced Management Program at Harvard Business School. Mr. Manwani also serves on the boards of Whirlpool Corporationrationration, Qualcomm Inc., Nielsen Holdings plc. and Tata Sons Private Limited.
Age: 64  Director Since 2018      
650 574-3000  www.gilead.com

Harish Manwani Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 0.08 % which means that it generated profit of $0.08 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.45 % meaning that it created $0.45 on every $100 dollars invested by stockholders.
The company currently holds 28.84 B in liabilities with Debt to Equity (D/E) ratio of 139.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Gilead Sciences has Current Ratio of 3.0 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Paul RothmanMerck Company
2015
Laurie GlimcherGlaxoSmithKline PLC
2017
James BloemAllergan Plc
2013
Christopher CoughlinAllergan Plc
2016
Manvinder BangaGlaxoSmithKline PLC
2016
Helen HobbsPfizer
2011
Jose BaselgaBristol Myers Squibb Company
2018
Karen WalkerEli Lilly And Company
2018
Pierre LandoltNovartis AG
1996
Christopher BodineAllergan Plc
2013
Wendell WeeksMerck Company
2004
Eugene WashingtonJohnson Johnson
2012
Robert BertoliniBristol Myers Squibb Company
2017
Adriane BrownAllergan Plc
2017
Karen HornEli Lilly And Company
2012
Pamela CraigMerck Company
2015
John NoseworthyMerck Company
2017
Nancy AndrewsNovartis AG
2015
Michael EskewEli Lilly And Company
2008
Suzanne JohnsonPfizer
2007
David HooverEli Lilly And Company
2009

Company Summary

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange.Gilead Sciences (GILD) is traded on BATS Exchange in USA. It is located in 333 Lakeside Drive, Foster City, CA 94404, United States and employs 11,000 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Gilead Sciences Leadership Team

Kathleen Watson, Executive Vice President - Human ResourcesView
John McHutchison, Executive Vice President - Clinical ResearchView
Andrew Cheng, Executive Vice President - HIV Therapeutics and Development OperationsView
John Martin, Chairman and CEOView
Andrew Dickinson, Executive Vice President - Corporate Development and StrategyView
Gayle Wilson, Independent DirectorView
Daniel ODay, Chairman of the Board, CEOView
Jacqueline Barton, DirectorView
Brett Pletcher, Executive VP and General CounselView
William Lee, Executive Vice President - ResearchView
John Madigan, Independent DirectorView
Martin Silverstein, Executive Vice President - StrategyView
Kevin Lofton, Independent DirectorView
Paul Carter, Executive Vice President - Commercial OperationsView
Gregg Alton, Executive VP of Corporate and Medical Affairs and SecretaryView
Diana Brainard, Senior Vice President HIV and Emerging Viral InfectionsView
Carla Hills, Independent DirectorView
John Cogan, Lead Independent DirectorView
John Milligan, Pres and COOView
Nicholas Moore, Independent DirectorView
James Meyers, Executive Vice President - Worldwide Commercial OperationsView
Katie Watson, Executive Vice President of Human ResourcesView
Kelly Kramer, DirectorView
Johanna Mercier, Chief Commercial OfficerView
Jyoti Mehra, Executive Vice President of Human ResourcesView
Laura Hamill, Executive Vice President - Worldwide Commercial OperationsView
Robin Washington, CFO and Executive VPView
Norbert Bischofberger, Chief Scientific Officer and Executive VP of RandDView
Per WoldOlsen, Independent DirectorView
Harish Manwani, DirectorView
Taiyin Yang, Executive Vice President - Pharmaceutical Development and ManufacturingView
Kevin Young, COOView
Etienne Davignon, Independent DirectorView
Richard Whitley, Independent DirectorView

Stock Performance Indicators

Current Sentiment - GILD

Gilead Sciences Investor Sentiment

Majority of Macroaxis users are currently bullish on Gilead Sciences. What is your judgment towards investing in Gilead Sciences? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Plese check Risk vs Return Analysis. Please also try Bollinger Bands module to use bollinger bands indicator to analyze target price for a given investing horizon.